Biologically Active Substance
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes
PTC crashes as win for Novartis-partnered Huntington’s drug fails to convince investors
factor IX, PTC518, Accelerated, Approved, United States Food and Drug Administration
PTC’s Novartis-partnered Huntington’s drug disappoints in mid-stage data reveal
PTC518, factor IX, Huntington ‘s disease, Market
FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme
United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO
Novo eyes fourth-quarter FDA verdict for oral Wegovy filing
Obesity, Novo, United States Food and Drug Administration, Decision, Oral cavity, Wegovy, semaglutide, Overweight
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases
Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring
Wegovy, Nordisk, LifeMD, Telemedicine, Access, CALR gene, Obesity, semaglutide, Adult